Rifampicin plus isoniazid for the prevention of tuberculosis in an immigrant population

International Journal of Tuberculosis and Lung Disease

Volumn 17, Issue 3, 2013, Pages 326-332

  Jimenez Fuentes M A ^a   De Souza Galvao, M L ^a   Mila Auge C ^a   Solsona Peiro J ^a   Altet Gomez M N ^a  

^a INSTITUT CATALÀ DE LA SALUT   (Spain)

Author keywords

Immigration; Isoniazid; Latent tuberculosis infection; Randomised clinical trial; Rifampicin

Indexed keywords

ISONIAZID; RIFAMPICIN;

ADULT; ANEMIA; ARTICLE; COMBINATION CHEMOTHERAPY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; EDUCATIONAL STATUS; FEMALE; FOLLOW UP; HUMAN; IMMIGRANT; INFECTION PREVENTION; LATENT TUBERCULOSIS; LEUKOPENIA; LIVER DISEASE; MAJOR CLINICAL STUDY; MALAISE; MALE; NAUSEA; PATIENT COMPLIANCE; PHOTOSENSITIVITY DISORDER; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SOCIAL SUPPORT; SPAIN; THROMBOCYTOPENIA; TREATMENT DURATION; UNEMPLOYMENT; VOMITING;

ADOLESCENT; ADULT; ANTITUBERCULAR AGENTS; CHI-SQUARE DISTRIBUTION; CHILD; DRUG ADMINISTRATION SCHEDULE; EMIGRANTS AND IMMIGRANTS; FEMALE; HUMANS; ISONIAZID; LATENT TUBERCULOSIS; LOGISTIC MODELS; MALE; MEDICATION ADHERENCE; MULTIVARIATE ANALYSIS; ODDS RATIO; PREVALENCE; PROSPECTIVE STUDIES; RIFAMPIN; RISK ASSESSMENT; RISK FACTORS; SOCIOECONOMIC FACTORS; SPAIN; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84874062953     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.12.0510     Document Type: Article

References (30)

1. World Health Organization. Global tuberculosis control 2010. WHO/HTM/TB/2010.7. Geneva, Switzerland: WHO, 2010.
2. Dye C, Scheele S, Dolin P, Pathania V, Raviglione M C. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence and mortality by country. WHO Global Surveillance and Monitoring project. JAMA 1999; 282: 677-686.
3. American Thoracic Society and Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infections. Am J Respir Care Med 2000; 161 (4 Pt 2): S221-S247.
4. Leung C C, Rieder H L, Lange C, Yew W W. Treatment of latent infection with Mycobacterium tuberculosis: update 2010. Respir J 2011; 37: 441-462.
5. Instituto Nacional de Estadística. Notas de prensa, 4 de abril 2011. Madrid, Spain: INE, 2011. http://www.ine.es/prensa/np648.pdf Accessed November 2012. [Spanish]
6. Ajuntament de Barcelona. Informes estadístics. La población extranjera a Barcelona. Barcelona, Spain: Ajuntament de Barcelona, 2011. http://www.bcn.cat/estadistica Accessed November 2012. [Catalan]
7. Orcau A, Rius i Gubert C, García de Olalla P, Caylà J A. La tuberculosi a Barcelona. Informe 2009. Programa de prevenció i control de Barcelona. Barcelona, Spain: Agéncia de Salut Pública de Barcelona, 2010. http://www.aspb.es/quefem/docs/Tuberculosi-2009.pdf Accessed November 2012. [Catalan]
8. Grupo de trabajo de los Talleres de 2001-2002 de la Unidad de Investigación de Barcelona. Prevención y control de las tuberculosis importadas. Med Clin (Bar) 2003; 121: 549-562. [Spanish]
9. Ruiz-Manzano J, Blanquer R, Calpe J L, et al. Normativa SEPAR. Diagnóstico y tratamiento de la tuberculosis. Arch Bronconeumol 2008; 44: 551-566. [Spanish]
10. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Organ 1982; 60: 555-564.
11. Comstock G W. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis 1999; 3: 847-850.
12. Horsburgh C R, Golberg S, Bethel J, Chen S, Colson P W, Hirsch-Moverman Y. Latent tuberculosis infection treatment. Acceptance and completion in the United States and Canada. Chest 2010; 137: 401-409.
13. Hong Kong Chest Service/Tuberculosis Research Centre Madras/British Medical Research Council. A double-blind placebo-controlled clinical trial of three anti-tuberculosis chemo-prophylaxis regimens in patients with silicosis in Hong Kong. Am Rev Respir Dis 1992; 145: 36-41.
14. Gordin F, Chaisson R E, Matts P J, et al. Rifampin and pyrazin-amide vs. isoniazid for prevention of tuberculosis in HIV-infected persons. An international randomized trial. JAMA 2000; 283: 1445-1450.
15. Centers of Disease Control and Prevention/American Thoracic Society. Update: fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations - United States, 2001. MMWR Morb Mortal Wkly Rep 2001; 50: 289-291.
16. Joint Tuberculosis Committee of the British Thoracic Society. Control and prevention of tuberculosis in the United Kingdom: code of practice 2000. Thorax 2000; 55: 887-901.
17. Sterkubg T R, Villarino E, Borisov A S. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 2011; 365: 3155-3166.
18. Mattelelli A M, Casalini C, Raviglione M. Supervised preventive therapy for latent tuberculosis infection in illegal immigrants in Italy. Am J Respir Crit Care Med 2000; 162: 1653-1655.
19. Grupo de Estudio de Contactos de la Unidad de Investigación en Tuberculosis de Barcelona (UITB). Documento de Consenso de sobre el estudio de contactos en los pacientes tuberculosos. Med Clin (Barc) 1999; 112: 151-156. [Spanish]
20. Eidus L, Hamilton E J. A new method for determination of N-acetyl isoniazid in urine of ambulatory patients. Am Rev Respir Dis 1964; 89: 587-588.
21. Ormerod L P. Rifampin and isoniazid prophylactic chemotherapy for tuberculosis. Arch Dis Child 1998; 78: 169-171.
22. Grupo de trabajo del area TIR de SEPAR. Normativa sobre la prevención de la tuberculosis. Arch Bronconeumol 2002; 38: 441-451. [Spanish]
23. Geijó M P, Herranz C R, Vaño D, Garcia J A, Garcia M, Dimas J F. Pauta corta de isoniazida y rifampicina comparada con isoniazida para la infección latente de tuberculosis. Ensayo clínico aleatorizado. Enferm Infecc Microbiol Clin 2007; 25: 300-304. [Spanish]
24. Salinas C, Pascual Erquicia S, Diez R, et al. Pauta de tres meses de rifampicina e isoniacida para el tratamiento de la infección latente tuberculosa. Med Clin (Barc) 2010; 135: 293-299. [Spanish]
25. Rivero A, Lopez-Cortes L, Castillo R, Verdejo J, Garcia M A, Martinez-Marcos J. Ensayo clínico aleatorizado para evaluar tres pautas cortas de tratamiento de la infección latente tuber-culosa en pacientes infectados por el HIV. Enferm Infecc Microbiol Clin 2007; 25: 305-310. [Spanish]
26. Ena J, Vall V. Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid for latent tuberculosis infection: a meta-analysis. Clin Infect Dis 2005; 40: 670-676.
27. Spyridis N P, Spyridis P G, Gelesme A, et al. The effectiveness of a 9-month regimen of isoniazid alone versus 3-and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. Clin Infect Dis 2007; 45: 715-722.
28. Bright-Thomas R, Nandwani S, Simith J, Morris J A, Ormerod L P. Effectiveness of 3 months of rifampicin and isoniazid chemoprophylaxis for the treatment of latent tuberculosis infection in children. Arch Dis Child 2010; 95: 600-602.
29. Cain K P, Benoit S R, Winston C A, Mac Kenzie W R. Tuberculosis among foreign-born persons in the United States. JAMA 2008; 300: 405-412.
30. Valles X, Sanchez F, Pañella H, Garcia de Olalla P, Jansa J M, Cayla J A. Tuberculosis importadas: una enfermedad emergente en países industrializados. Med Clin (Bar) 2002; 118: 376-378. [Spanish]